Daily close, T-120 (4/8/25) through T+5. Run-up high $10.09 on 9/11/25, low $6.97 on 4/17/25 (T-120 to T-1). FDA decision 9/23/25. Historical price action, not a forecast.
Positioning before the decision
On Sep 9, 2025, 14 days before the decision date, at-the-money options priced a move of ±10.9% through Oct 17, 2025 (the first listed expiry after the decision; ATM implied volatility 84%). The stock closed -1.6% at the first close across the decision and -1.3% five trading days on. A straddle priced weeks out covers ordinary movement plus the event, so this is the move the options market priced through that expiry, not the event-implied move alone. How this compares across 1,000+ decisions.
Was Bimatoprost ophthalmic solution (Lumigan generic) approved by the FDA?
Yes. The FDA approved the application for Bimatoprost ophthalmic solution (Lumigan generic) on September 23, 2025. The primary source is linked on this page.
What was Bimatoprost ophthalmic solution (Lumigan generic) under FDA review for?
The application covered Open angle glaucoma or ocular hypertension. The FDA approved the application on September 23, 2025.
How did AMRX stock react to the FDA decision?
On the decision day AMRX moved -1.6%. That is the recorded reaction to this specific event -- historical measurement, not a prediction, and not investment advice.